Gastroenterology
Volume 136, Issue 2 , Pages 451-458, February 2009

Risk of Cervical Abnormalities in Women With Inflammatory Bowel Disease: A Population-Based Nested Case-Control Study

  • Harminder Singh

      Affiliations

    • Internal Medicine, and the University of Manitoba IBD Clinical and Research Centre, Winnipeg, Manitoba, Canada
    • Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
    • Corresponding Author InformationAddress requests for reprints to: Harminder Singh, MD, Section of Gastroenterology, 804-715 McDermot Avenue, Winnipeg, Manitoba, Canada R3E3P4. fax: (204) 789-3972
  • ,
  • Alain A. Demers

      Affiliations

    • Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
    • Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, Manitoba, Canada
  • ,
  • Zoann Nugent

      Affiliations

    • Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, Manitoba, Canada
  • ,
  • Salaheddin M. Mahmud

      Affiliations

    • Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
    • Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, Manitoba, Canada
  • ,
  • Erich V. Kliewer

      Affiliations

    • Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
    • Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, Manitoba, Canada
  • ,
  • Charles N. Bernstein

      Affiliations

    • Internal Medicine, and the University of Manitoba IBD Clinical and Research Centre, Winnipeg, Manitoba, Canada

Received 19 May 2008; accepted 9 October 2008. published online 16 October 2008.

Background & Aims

We evaluated the risk of cervical abnormalities in women with inflammatory bowel disease (IBD) in a population-based, nested, case-control study.

Methods

Cases with abnormal Papanicolaou (Pap) smears or cervical biopsies were matched with up to 3 controls (normal Pap smears) by year of birth, year of first health care coverage, and number of Pap smears in the preceding 5 years. A diagnosis of IBD before the index date was identified from the University of Manitoba IBD Epidemiology Database. Exposures to immunosuppressant drugs and corticosteroids were determined from the provincial drug prescription database. Analyses were adjusted for socioeconomic status and exposure to oral contraceptives and nonsteroidal anti-inflammatory drugs.

Results

19,692 women with cervical cytologic and/or histologic abnormalities were matched with 57,898 controls with normal Pap smears. There was no association between cervical abnormalities and ulcerative colitis (odds ratio [OR], 1.03; 95% confidence interval [CI], 0.77–1.38). The increase in risk in women with Crohn's disease was limited to those exposed to 10 or more prescriptions of oral contraceptives (OR, 1.66; 95% CI, 1.08–2.54). The combined exposure to corticosteroids and immunosuppressants was associated with increased risk of cervical abnormalities (OR, 1.41; 95% CI, 1.09–1.81). There was no interaction between the effect of IBD and corticosteroids and/or immunosuppressants.

Conclusions

These findings do not support an association between IBD itself and the risk of developing cervical abnormalities. An increased risk in patients given a combination of corticosteroids and immunosuppressants should be considered in managing women with IBD.

Abbreviations used in this paper: CI, confidence interval, HPV, human papillomavirus, MCCSP, Manitoba Cervical Cancer Screening Program, MCR, Manitoba Cancer Registry, NSAID, nonsteroidal anti-inflammatory drug, OCP, oral contraceptive pills, OR, odds ratio, Pap, Papanicolaou's, SES, socioeconomic status

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The authors disclose the following: Funding for this study was provided by the Manitoba Medical Services Foundation. H.S. is supported in part by a Dr F. W. Du Val Clinical Research Professorship Award. C.N.B. is supported in part by a Research Scientist Award of the Crohn's and Colitis Foundation of Canada.

 The results and conclusions are those of the authors, and no official endorsement by Manitoba Health and Healthy Living is intended or should be inferred.

PII: S0016-5085(08)01857-X

doi:10.1053/j.gastro.2008.10.021

Gastroenterology
Volume 136, Issue 2 , Pages 451-458, February 2009